Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06865571 ± PF-05221304 in NASH With Fibrosis
CTR20210412Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ervogastat, clesacostat in metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Pfizer. Started Mar 2021; status: completed.
02
Drugs
ervogastatclesacostat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on CTR20210412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210412.